CAR-T Engager Proteins Optimize Anti-CD19 CAR-T Cell Therapies for Lymphoma

The authors designed a unique therapeutic to prevent and reverse relapses due to lost or reduced CD19 expression. This novel biologic, a CAR T Engager, bound CD20 and displayed the CD19 extracellular domain.